Hi Edmorgrimm, good to hear from you, and of course all your comments I'd agree with 100%.
Yes its not hard to overlook the company since we're in a period where assumedly the work is being put into the statistical analysis of results and the other aspects in preparation for FDA application submission. Certainly it will be interesting to hear what John McCutcheon presents at the Webinar. (I'm still overseas but hope to be available to hear the presentation).
Your remark regarding it being a potential multi-bagger is something that I'm certainly focused on - I've listened to a few finance guys over the past 2 weeks reminding me of how PME moved from 45 cents up to around $65 over the past 10 years - and each of the 3 were happy to point out how they got it reasonably early. In fact i actually had 10,000 shares in PME at around 85 cents, only to sell out because it fell away and i thought that i could make a better return off a resource share. Silly me! I don't look at PME at all nowadays (but still get reminded by certain holders from time to time) but I've learnt my lesson.
I've actually purchased more shares in EBR over the past couple of months (at higher prices), and certainly I continue to accumulate every now and then - its 1 of 2 companies I consider will ultimately be re-rated once FDA approval is granted, and commercialisation begins.
I should also mention that the interviews Pt1&2) with Allan Will were quite enlightening, confirming the very high standing he has in the medical apparatus and associated industries, and his amazing association with each of the current leaders in heart pacemaker technology that I'm sure will add value for all EBR shareholders.
Mind you I'm certain the share price will remain low until more positive news is forthcoming - investors in general are very impatient (just as i was with PME).
Stay strong and steadfast is my view!
EBR Price at posting:
83.5¢ Sentiment: Buy Disclosure: Held
(20min delay)